Dolastatin 10 in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Previous Hormone Therapy

Completed · Phase 2

Conditions studied: Prostate Cancer

In brief

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of dolastatin 10 in treating patients with metastatic prostate cancer that has not responded to previous hormone therapy.

Key facts

Study ID

NCT00003626

Run by

Barbara Ann Karmanos Cancer Institute

Starts

1998-10-01

Expected to finish

2000-05-01

Last updated by the study team

2013-04-05

Who can join

Age: any. Sex: male. Healthy volunteers: not accepted.

Where it is running

• University of Colorado Cancer Center — Denver, Colorado, United States
• Barbara Ann Karmanos Cancer Institute — Detroit, Michigan, United States
• Fox Chase Cancer Center — Philadelphia, Pennsylvania, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.